Company news
Incyte Corporation news in 2019
Incyte Corporation's news releases, calls and decks from 2019, newest first.
Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
November 26, 2019
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting
November 24, 2019
Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 28, 2019
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
October 15, 2019
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
October 11, 2019
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
September 26, 2019
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
September 24, 2019
Incyte to Host Investor Conference Call from ESMO 2019
September 22, 2019
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
August 22, 2019
Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019
March 31, 2019